-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Cabometyx in Pancreatic Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Cabometyx in Pancreatic Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Cabometyx in Pancreatic Cancer Drug Details: Cabozantinib s-malate (Cabometyx, Aptimetyx) is a...
-
Product Insights
Alcohol Addiction – Drugs In Development, 2023
Global Markets Direct’s, ‘Alcohol Addiction - Drugs In Development, 2023’, provides an overview of the Alcohol Addiction pipeline landscape. The report provides comprehensive information on the therapeutics under development for Alcohol Addiction, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Opium (Opioid) Addiction – Drugs In Development, 2023
Global Markets Direct’s, ‘Opium (Opioid) Addiction - Drugs In Development, 2023’, provides an overview of the Opium (Opioid) Addiction pipeline landscape. The report provides comprehensive information on the therapeutics under development for Opium (Opioid) Addiction, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – KNX-100 in Opium (Opioid) Addiction
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - KNX-100 in Opium (Opioid) Addiction report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.KNX-100 in Opium (Opioid) Addiction Drug Details:KNX-100 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – RAB-001 in Osteoporosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - RAB-001 in Osteoporosis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.RAB-001 in OsteoporosisDrug Details:RAB-001 is under development for the treatment of osteoporosis, osteonecrosis, fracture...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – KNX-100
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry KNX-100 Drug Details KNX-100 is under development for the treatment of alcohol addiction and...
-
Product Insights
Opium (Opioid) Addiction Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Opium (Opioid) Addiction develops after using opioids regularly for a period. Prolonged use of opiates can lead to nerve damage within the brain that causes cells to stop producing endogenous opiates (natural painkillers known as endorphins). Its signs and symptoms include increased general anxiety, euphoria, psychosis, depression, high blood pressure, decreased appetite, physical agitation, difficulty sleeping, and pain in the bones. The predisposing factors include age, personal history/ family history of substance abuse, cigarette dependency, and psychological stress. The Opium...
-
Product Insights
Alcohol Addiction Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
The Alcohol Addiction pipeline market research report provides comprehensive information on the therapeutics under development for Alcohol Addiction, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Alcohol Addiction and features dormant...
-
Product Insights
Drug Addiction Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Drug addiction, also called substance dependence or chemical dependency, is a disease that is characterized by a destructive pattern of drug abuse that leads to significant problems involving tolerance to or withdrawal from the substance. Drug addiction symptoms or behaviors include recurrent drug use that results in a lack of meeting important obligations at work, school, or home, inability to sleep, awake at unusual times, unusual laziness, loss of or increased in appetite, changes in eating habits, cold, sweaty palms;...